Evogliptin tartrate is a highly potent, orally bioavailable and specific dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity. Evogliptin tartrate has highly potential for anti-atherosclerosis therapy that targets arterial inflammation. References: [1]. Modulation of Sirt1/NF-κB interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque formation. Biochem Pharmacol. 2019 Oct;168:452-464.

纯度：≥98%

CAS：1222102-51-3